Seqirus - NERVODERM lidocaine (lignocaine) 5% w/w dermal patch

Therapeutic Goods Act 1989

Approval under section 42DF for use of restricted representations by Seqirus Pty Ltd

I, Leanne McCauley, Delegate of the Secretary to the Department of Health, on receipt of an application from Seqirus Pty Ltd, have approved under section 42DF of the Therapeutic Goods Act 1989 (the Act) the restricted representations described in paragraph (A) below for use in advertisements directed to consumers, for the products identified in paragraph (B):

1.  
   • Nervoderm relieves medically diagnosed post-shingles pain;
   • Nervoderm relieves medically diagnosed persistent nerve pain following shingles;
   • Nervoderm relieves medically diagnosed post-shingle nerve pain;
   • Nervoderm relieves medically diagnosed post-shingles nerve pain (also known as post herpetic-neuralgia); and/or
   • Nervoderm relieves pain associated with medically diagnosed post-shingles pain (also known as post-herpetic neuralgia).
2. NERVODERM lidocaine (lignocaine) 5% w/w dermal patch (AUST R 280081)

Dated this 5th day of November 2020

Signed electronically

Leanne McCauley
Delegate of the Secretary to the Department of Health
Advertising Education and Assurance Section
Regulatory Compliance Branch